Autolus Therapeutics PLC
NASDAQ:AUTL
Gross Margin
Autolus Therapeutics PLC
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| UK |
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
412.5m USD |
-80%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
0%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
385.2B USD |
71%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
160.6B USD |
70%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
148.8B USD |
79%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
76%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
109.1B USD |
86%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
68.6B USD |
86%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
59.7B USD |
84%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
84.9B AUD |
52%
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.4B EUR |
90%
|
Autolus Therapeutics PLC
Glance View
Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. The firm is focused on developing programmed T cell therapies for the treatment of cancer. The firm has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. Its lead clinical programs include AUTO1 (obecabtagene autoleucel, Obe-Cel), AUTO4, and AUTO6 / AUTO6NG. Obe-cel is a CD19 CAR T cell investigational therapy designed to overcome limitations in clinical activity and safety. Obe-cel reduces toxicity and is less prone to T cell exhaustion, which could improve persistence and the ability of programmed T cells to engage in serial killing of target cancer cells. AUTO4 is a T cell therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1. AUTO6 / AUTO6NG is a T cell therapy targeting GD2 in development for the treatment of neuroblastoma. Its other clinical programs include AUTO5, AUTO7, and AUTO8.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Autolus Therapeutics PLC's most recent financial statements, the company has Gross Margin of -79.7%.